On April 12, 2023 Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), reported that it has secured $5 million in its Series A3 round (Press release, Geneos Therapeutics, APR 12, 2023, View Source [SID1234630017]). This financing adds 3B Future Health Fund (3B FHF) to Geneos’ investor syndicate. Further, Dr. Roberto DePonti, managing director and general partner of 3B FHF, joins Geneos as a board observer, adding decades of pharmaceutical drug development experience to the company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Proceeds Will Fund Expansion of Phase 1b/2a GT-30 Program
GT-30 is evaluating safety, immunogenicity, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) administered in combination with the immune checkpoint inhibitor pembrolizumab, in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who progress on, or are intolerant to, first line tyrosine kinase inhibitors (sorafenib or lenvatinib). The company previously reported data from the first 24 patients enrolled showing strong tumor reductions including three complete responses (complete disappearance of tumor), and four patients with a partial response. Based on these encouraging results, the study enrollment was expanded to 36 patients. Geneos plans to report the efficacy and durability of response data from the full cohort of 36 patients in 2023.
"We are excited to contribute to the development of Geneos’ advanced approach to treat, patients with HCC as well as multiple additional types of cancer in the future," stated Riccardo Braglia, general partner of 3B Future Health Fund II. "We are encouraged by the very promising results in the current clinical trial and look forward to working closely with the talented Geneos team."
"We are delighted to welcome Roberto and 3B FHF into our investor syndicate. We look forward to working with 3B FHF and their strong worldwide pharmaceutical development expertise and broad network in advancing our novel personalized therapeutic cancer vaccines," stated Niranjan Sardesai, PhD., president and chief executive officer of Geneos Therapeutics.